Xiaofei Wang | Scholars@Duke

Xiaofei Wang
Associate Professor of Biostatistics and Bioinformatics

Design and Analysis of Clinical Trials
Nonparametric and Semiparametric Methods
Survival Analysis
Statistical Methods for Diagnostic and Predictive Medicine
Biomarker Discovery and Validation
Health Outcomes Research

Current Appointments & Affiliations

Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2012
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2015

Contact Information

2424 Erwin Road Suite 1102, 11080 Hock Plaza, Duke Box 272, Durham, NC 27705
Duke Box 2721, Durham, NC 27710
xiaofei.wang@duke.edu (919) 681-5406

Background
Education, Training, & Certifications
- Graduate Research Assistant, Biostatistics, University of North Carolina at Chapel Hill 1996 - 2003
- Ph.D., University of North Carolina at Chapel Hill 2003
- Graduate Research Assistant, Computer Sciences, University of North Carolina at Chapel Hill 1994 - 1996
Duke Appointment History
- Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2007 - 2012
- Assistant Research Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2004 - 2007
- Instructor, Temporary of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2003
Expertise
Global Scholarship
- Expertise
  - China (Country)
Research
Selected Grants
- Alliance NCORP Research Base awarded by Mayo Clinic 2014 - 2019
- Administrative Core awarded by University of North Carolina - Chapel Hill 2015 - 2019
- Innovative Biomarker-Integrated Clinical Trial Design and Analysis awarded by University of North Carolina - Chapel Hill 2015 - 2019
- Methods for Discovery and Analysis of Dynamic Treatment Regimes awarded by University of North Carolina - Chapel Hill 2015 - 2019
- Alliance for Clinical Trials in Oncology awarded by Mayo Clinic 2017 - 2019
- Alliance for Clinical Trials in Oncology awarded by Brigham and Women's Hospital 2014 - 2019
- Alliance for Clinical Trials in Oncology awarded by Mayo Clinic 2017 - 2018
- National Clinical Trials Network - Network Group Statistics and DMCs awarded by Mayo Clinic 2014 - 2017
- Translational meta-analysis for elderly lung cancer patients awarded by National Institutes of Health 2013 - 2016
- Cancer and Leukemia Group B Statistical Center awarded by National Institutes of Health 1982 - 2010
- Semiparametric ROC Curve Regression for Cancer Screening Studies awarded by National Institutes of Health 2007 - 2010
Publications & Artistic Works
Selected Publications
- Books
  - Jung, S. H. Design and analysis of phase II cancer clinical trials, 2016. https://doi.org/10.1201/9781315371566.
    Full Text
- Academic Articles
  - Hamy, Anne-Sophie, Sandrine Tury, Xiaofei Wang, Junheng Gao, Jean-Yves Pierga, Sylvie Giacchetti, Etienne Brain, et al. “Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 37, no. 8 (March 2019): 624–35. https://doi.org/10.1200/jco.18.00636.
    Full Text
  - Ganti, Apar Kishor, Xiaofei Wang, Thomas E. Stinchcombe, Yinpeng Wang, Jeffrey Bradley, Harvey J. Cohen, Karen Kelly, et al. “Clinical prognostic model for older patients with advanced non-small cell lung cancer..” Journal of Geriatric Oncology, February 20, 2019. https://doi.org/10.1016/j.jgo.2019.02.007.
    Full Text
  - Schild, Steven E., Wen Fan, Thomas E. Stinchcombe, Everett E. Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Karen Kelly, Herbert H. Pang, and Xiaofei Wang. “Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer..” J Thorac Oncol 14, no. 2 (February 2019): 298–303. https://doi.org/10.1016/j.jtho.2018.09.021.
    Full Text Link to Item
  - Stinchcombe, Thomas E., Wen Fan, Steven E. Schild, Everett E. Vokes, Jeff Bogart, Quynh-Thu Le, Charles R. Thomas, et al. “A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients..” Cancer 125, no. 3 (February 2019): 382–90. https://doi.org/10.1002/cncr.31813.
    Full Text
  - Yang, Chi-Fu Jeffrey, Derek Y. Chan, Shivani A. Shah, Babatunde A. Yerokun, Xiaofei F. Wang, Thomas A. D’Amico, Mark F. Berry, and David H. Harpole. “Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer..” Annals of Surgery 268, no. 6 (December 2018): 1105–12. https://doi.org/10.1097/sla.0000000000002287.
    Full Text
  - Altorki, NK, Wang, X, Wigle, D, Gu, L, Darling, G, Ashrafi, AS, Landrenau, R, Miller, D, Liberman, M, Jones, DR, Keenan, R, Conti, M, Wright, G, Veit, LJ, Ramalingam, SS, Kamel, M, Pass, HI, Mitchell, JD, Stinchcombe, T, Vokes, E, and Kohman, LJ. "Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)." The Lancet. Respiratory Medicine 6, no. 12 (December 2018): 915-924. Full Text
  - Li, Zhiguo, Xiaofei Wang, Yuan Wu, and Kouros Owzar. “Sample size calculation for studies with grouped survival data..” Statistics in Medicine 37, no. 27 (November 2018): 3904–17. https://doi.org/10.1002/sim.7847.
    Full Text Open Access Copy
  - Wang, Ting, Xiaofei Wang, Haibo Zhou, Jianwen Cai, and Stephen L. George. “Auxiliary variable-enriched biomarker-stratified design..” Statistics in Medicine, September 16, 2018. https://doi.org/10.1002/sim.7938.
    Full Text
  - Kinsey, Emily, Elizabeth Ajazi, Xiaofei Wang, Mary Ann Mayzie Johnston, and Jeffrey Crawford. “Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy..” J Thorac Oncol 13, no. 9 (September 2018): 1294–1301. https://doi.org/10.1016/j.jtho.2018.05.029.
    Full Text Link to Item
  - Schild, Steven E., Herbert H. Pang, Wen Fan, Thomas E. Stinchcombe, Everett E. Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Karen Kelly, and Xiaofei Wang. “Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC..” J Thorac Oncol 13, no. 8 (August 2018): 1171–82. https://doi.org/10.1016/j.jtho.2018.04.011.
    Full Text Link to Item
  - Urbanic, James J., Xiaofei Wang, Jeffrey A. Bogart, Thomas E. Stinchcombe, Lydia Hodgson, Steven E. Schild, Lyudmila Bazhenova, Olwen Hahn, Ravi Salgia, and Everett E. Vokes. “Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance)..” International Journal of Radiation Oncology, Biology, Physics 101, no. 1 (May 2018): 177–85. https://doi.org/10.1016/j.ijrobp.2018.01.046.
    Full Text
  - Yang, Chi-Fu Jeffrey, Frances McSherry, Nicholas R. Mayne, Xiaofei Wang, Mark F. Berry, Betty Tong, David H. Harpole, et al. “Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer..” Ann Thorac Surg 105, no. 3 (March 2018): 924–29. https://doi.org/10.1016/j.athoracsur.2017.09.030.
    Full Text Link to Item
  - Nasution, Marlina D., and Xiaofei Wang. “Statistical issues and advances in cancer precision medicine research..” Journal of Biopharmaceutical Statistics 28, no. 2 (January 2018): 215–16. https://doi.org/10.1080/10543406.2017.1405013.
    Full Text
  - Wang, Xiaofei, Jingzhu Zhou, Ting Wang, and Stephen L. George. “On Enrichment Strategies for Biomarker Stratified Clinical Trials..” Journal of Biopharmaceutical Statistics 28, no. 2 (January 2018): 292–308. https://doi.org/10.1080/10543406.2017.1379532.
    Full Text Open Access Copy
  - Yang, Chi-Fu Jeffrey, Hanghang Wang, Arvind Kumar, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D’Amico, and Mark F. Berry. “Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma..” Chest 152, no. 6 (December 2017): 1239–50. https://doi.org/10.1016/j.chest.2017.07.032.
    Full Text
  - Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
    Full Text
  - Stinchcombe, Thomas E., Ying Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Karen Kelly, Walter J. Curran, et al. “Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies..” J Clin Oncol 35, no. 25 (September 1, 2017): 2885–92. https://doi.org/10.1200/JCO.2016.71.4758.
    Full Text Link to Item
  - Yao, Xiaoxin I., Xiaofei Wang, Paul J. Speicher, E Shelley Hwang, Perry Cheng, David H. Harpole, Mark F. Berry, Deborah Schrag, and Herbert H. Pang. “Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies..” Journal of the National Cancer Institute 109, no. 8 (August 2017). https://doi.org/10.1093/jnci/djw323.
    Full Text
  - Yerokun, Babatunde A., Chi-Fu Jeffrey Yang, Brian C. Gulack, Xuechan Li, Michael S. Mulvihill, Lin Gu, Xiaofei Wang, et al. “A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer..” The Journal of Thoracic and Cardiovascular Surgery 154, no. 2 (August 2017): 675-686.e4. https://doi.org/10.1016/j.jtcvs.2017.02.065.
    Full Text
  - Edelman, Martin J., Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Sachdev P. Thomas, Ajeet Gajra, et al. “Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 19 (July 2017): 2184–92. https://doi.org/10.1200/JCO.2016.71.3743.
    Full Text
  - Kohman, Leslie J., Lin Gu, Nasser Altorki, Ernest Scalzetti, Linda J. Veit, Jason M. Wallen, and Xiaofei Wang. “Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503..” The Journal of Thoracic and Cardiovascular Surgery 153, no. 6 (June 2017): 1592–97. https://doi.org/10.1016/j.jtcvs.2016.12.045.
    Full Text
  - Baggstrom, M. Q., M. A. Socinski, X. F. Wang, L. Gu, T. E. Stinchcombe, M. J. Edelman, S. Baker, et al. “Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance).” Journal of Thoracic Oncology 12, no. 5 (May 1, 2017): 843–49. https://doi.org/10.1016/j.jtho.2017.01.022.
    Full Text
  - Baggstrom, Maria Q., Mark A. Socinski, Xiaofei F. Wang, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker, et al. “Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)..” J Thorac Oncol 12, no. 5 (May 2017): 843–49. https://doi.org/10.1016/j.jtho.2017.01.022.
    Full Text Link to Item
  - Edelman, M. J., X. Wang, L. Hodgson, R. T. Cheney, M. Q. Baggstrom, T. Sachdev, A. Gajra, et al. “Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance)..” International Journal of Radiation Oncology, Biology, Physics 98, no. 1 (May 2017): 220–21. https://doi.org/10.1016/j.ijrobp.2017.01.038.
    Full Text
  - Augert, Arnaud, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, and David MacPherson. “Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 12, no. 4 (April 2017): 704–13. https://doi.org/10.1016/j.jtho.2016.12.011.
    Full Text
  - Cox, Morgan L., Chi-Fu Jeffrey Yang, Paul J. Speicher, Kevin L. Anderson, Zachary W. Fitch, Lin Gu, Robert Patrick Davis, et al. “The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 12, no. 4 (April 2017): 689–96. https://doi.org/10.1016/j.jtho.2017.01.003.
    Full Text
  - Hwang, E Shelley, and Xiaofei Wang. “Value of Propensity Score Matching to Study Surgical Outcomes..” Annals of Surgery 265, no. 3 (March 2017): 457–58. https://doi.org/10.1097/sla.0000000000002125.
    Full Text
  - Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, et al. “Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials..” Oncologist 22, no. 2 (February 2017): 189–98. https://doi.org/10.1634/theoncologist.2016-0121.
    Full Text Link to Item
  - Torok, Jordan A., Lin Gu, Daniel J. Tandberg, Xiaofei Wang, David H. Harpole, Chris R. Kelsey, and Joseph K. Salama. “Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer..” Clinical Lung Cancer 18, no. 1 (January 2017): e57–70. https://doi.org/10.1016/j.cllc.2016.06.011.
    Full Text
  - Wang, X., K. Chen, Y. Yu, Y. Xiang, J. H. Kim, W. Gong, J. Huang, et al. “Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib.” Oncotarget 8, no. 65 (January 1, 2017): 109068–78. https://doi.org/10.18632/oncotarget.22596.
    Full Text
  - Wang, Xiao-Fei, Yi-Tong Zhu, Jia-Jia Wang, Da-Xiong Zeng, Chuan-Yong Mu, Yan-Bin Chen, Wei Lei, Ye-Han Zhu, and Jian-An Huang. “The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients..” Plos One 12, no. 9 (January 2017): e0185168–e0185168. https://doi.org/10.1371/journal.pone.0185168.
    Full Text
  - Yang, Chi-Fu Jeffrey, Derek Y. Chan, Xiaofei Wang, Thomas A. D’Amico, David H. Harpole, and Mark F. Berry. “Reply to T.-H. Wang et al..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 1 (January 2017): 118–20. https://doi.org/10.1200/jco.2016.68.6980.
    Full Text
  - Pang, Herbert H., Xiaofei Wang, Thomas E. Stinchcombe, Melisa L. Wong, Perry Cheng, Apar Kishor Ganti, Daniel J. Sargent, et al. “Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012..” J Clin Oncol 34, no. 33 (November 20, 2016): 3992–99. https://doi.org/10.1200/JCO.2016.67.7088.
    Full Text Link to Item
  - De Ruysscher, D., B. Lueza, C. Le Péchoux, D. H. Johnson, M. O’Brien, N. Murray, S. Spiro, et al. “Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 27, no. 10 (October 2016): 1818–28. https://doi.org/10.1093/annonc/mdw263.
    Full Text
  - Huang, Aimi, Rong Li, Jikai Zhao, Xiaofei Wang, Bo Jin, Yanjie Niu, Jie Zhang, Liyan Jiang, and Baohui Han. “Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation..” Thoracic Cancer 7, no. 5 (September 2016): 614–18. https://doi.org/10.1111/1759-7714.12364.
    Full Text
  - Wang, L., B. Wang, S. R. Chen, X. Hou, X. F. Wang, S. H. Zhao, J. Q. Song, and Y. G. Wang. “Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves' Disease: A Prospective Pilot Study..” Hormone and Metabolic Research = Hormon Und Stoffwechselforschung = Hormones Et Metabolisme 48, no. 9 (September 2016): 559–64. https://doi.org/10.1055/s-0042-110491.
    Full Text
  - Boyer, Matthew J., Lin Gu, Xiaofei Wang, Chris R. Kelsey, David S. Yoo, Mark W. Onaitis, Frank R. Dunphy, Jeffrey Crawford, Neal E. Ready, and Joseph K. Salama. “Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer..” Lung Cancer (Amsterdam, Netherlands) 98 (August 2016): 76–78. https://doi.org/10.1016/j.lungcan.2016.05.014.
    Full Text
  - Zhu, Zhaoyin, Xiaofei Wang, Paramita Saha-Chaudhuri, Andrzej S. Kosinski, and Stephen L. George. “Time-dependent classification accuracy curve under marker-dependent sampling..” Biometrical Journal. Biometrische Zeitschrift 58, no. 4 (July 2016): 974–92. https://doi.org/10.1002/bimj.201500171.
    Full Text
  - Martin, Linda W., Jonathan D’Cunha, Xiaofei Wang, Debra Herzan, Lin Gu, Naif Abraham, Todd L. Demmy, et al. “Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 13 (May 2016): 1484–91. https://doi.org/10.1200/JCO.2015.63.4543.
    Full Text
  - Yang, Chi-Fu Jeffrey, Arvind Kumar, Brian C. Gulack, Michael S. Mulvihill, Matthew G. Hartwig, Xiaofei Wang, Thomas A. D’Amico, and Mark F. Berry. “Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis..” The Journal of Thoracic and Cardiovascular Surgery 151, no. 5 (May 2016): 1380–88. https://doi.org/10.1016/j.jtcvs.2015.12.028.
    Full Text
  - Yang, Chi-Fu Jeffrey, Derek Y. Chan, Paul J. Speicher, Brian C. Gulack, Xiaofei Wang, Matthew G. Hartwig, Mark W. Onaitis, et al. “Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 10 (April 2016): 1057–64. https://doi.org/10.1200/JCO.2015.63.8171.
    Full Text
  - Speicher, Paul J., Brian R. Englum, Asvin M. Ganapathi, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D’Amico, and Mark F. Berry. “Traveling to a High-volume Center is Associated With Improved Survival for Patients With Esophageal Cancer..” Annals of Surgery, March 15, 2016.
  - Salama, Joseph K., Lin Gu, Xiaofei Wang, Herbert H. Pang, Jeffrey A. Bogart, Jeffrey Crawford, Steven E. Schild, Everett E. Vokes, and Neal E. Ready. “Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)..” J Thorac Oncol 11, no. 3 (March 2016): 361–69. https://doi.org/10.1016/j.jtho.2015.11.001.
    Full Text Link to Item
  - Wang, Xiaofei, and Mark F. Berry. “Risk calculators are useful but.....” The Journal of Thoracic and Cardiovascular Surgery 151, no. 3 (March 2016): 706–7. https://doi.org/10.1016/j.jtcvs.2015.09.058.
    Full Text
  - Pang, Herbert, and Xiaofei Wang. “Statistical aspect of translational and correlative studies in clinical trials..” Chinese Clinical Oncology 5, no. 1 (February 2016). https://doi.org/10.3978/j.issn.2304-3865.2014.07.04.
    Full Text
  - Speicher, Paul J., Lin Gu, Brian C. Gulack, Xiaofei Wang, Thomas A. D’Amico, Matthew G. Hartwig, and Mark F. Berry. “Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States..” Clinical Lung Cancer 17, no. 1 (January 2016): 47–55. https://doi.org/10.1016/j.cllc.2015.07.005.
    Full Text
  - Xia, Fang, Stephen L. George, and Xiaofei Wang. “A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression..” Statistics in Biopharmaceutical Research 8, no. 1 (January 2016): 12–21. https://doi.org/10.1080/19466315.2015.1093539.
    Full Text
  - Clarke, Jeffrey M., Xiaofei Wang, and Neal E. Ready. “Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?.” Translational Lung Cancer Research 4, no. 6 (December 2015): 804–8. https://doi.org/10.3978/j.issn.2218-6751.2015.05.03.
    Full Text
  - Gulack, Brian C., Chi-Fu Jeffrey Yang, Paul J. Speicher, James M. Meza, Lin Gu, Xiaofei Wang, Thomas A. D’Amico, Matthew G. Hartwig, and Mark F. Berry. “The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer..” Lung Cancer 90, no. 3 (December 2015): 554–60. https://doi.org/10.1016/j.lungcan.2015.10.011.
    Full Text Link to Item
  - Yang, Chi-Fu Jeffrey, Brian C. Gulack, Lin Gu, Paul J. Speicher, Xiaofei Wang, David H. Harpole, Mark W. Onaitis, Thomas A. D’Amico, Mark F. Berry, and Matthew G. Hartwig. “Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer..” The Journal of Thoracic and Cardiovascular Surgery 150, no. 6 (December 2015): 1484–92. https://doi.org/10.1016/j.jtcvs.2015.06.062.
    Full Text
  - Zhao, J., Y. Zhao, T. Qiu, W. Jiao, Y. Xuan, X. Wang, Y. Wang, and Y. Luo. “Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy..” Indian Journal of Cancer 52 Suppl 2 (December 2015): e130–33. https://doi.org/10.4103/0019-509x.172510.
    Full Text
  - Speicher, P. J., X. Wang, B. R. Englum, A. M. Ganapathi, B. Yerokun, M. G. Hartwig, T. A. D’Amico, and M. F. Berry. “Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer..” Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus 28, no. 8 (November 2015): 788–96. https://doi.org/10.1111/dote.12285.
    Full Text
  - Wang, Xiaofei, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, et al. “Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups..” Lung Cancer (Amsterdam, Netherlands) 90, no. 2 (November 2015): 281–87. https://doi.org/10.1016/j.lungcan.2015.08.007.
    Full Text
  - Salama, Joseph K., Lin Gu, Xiaofei Wang, Jeffrey Bogart, Jeffrey Crawford, Steven Schild, Neal Ready, and Everett Vokes. “PCI Survival Improvement for Extensive Stage SCLC Limited to Patients on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 30504.” Journal of Thoracic Oncology 10, no. 9 (September 1, 2015): S401–S401.
    Link to Item
  - Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, et al. “Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 10, no. 7 (July 2015): 1099–1106. https://doi.org/10.1097/JTO.0000000000000548.
    Full Text
  - Speicher, Paul J., Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D’Amico, and Mark F. Berry. “Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?.” Journal of the National Comprehensive Cancer Network : Jnccn 13, no. 6 (June 2015): 755–61. https://doi.org/10.6004/jnccn.2015.0090.
    Full Text
  - Nwogu, Chukwumere E., Jonathan D’Cunha, Herbert Pang, Lin Gu, Xiaofei Wang, William G. Richards, Linda J. Veit, et al. “VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance)..” The Annals of Thoracic Surgery 99, no. 2 (February 2015): 399–405. https://doi.org/10.1016/j.athoracsur.2014.09.018.
    Full Text
  - Lilenbaum, Rogerio, Michael Samuels, Xiaofei Wang, Feng Ming Kong, Pasi A. Jänne, Gregory Masters, Sreedhar Katragadda, et al. “A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 10, no. 1 (January 2015): 143–47. https://doi.org/10.1097/JTO.0000000000000347.
    Full Text
  - Nwogu, C. E., J. D’Cunha, H. Pang, L. Gu, X. Wang, W. G. Richards, L. J. Veit, et al. “VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance).” Annals of Thoracic Surgery 99, no. 2 (January 1, 2015): 399–405. https://doi.org/10.1016/j.athoracsur.2014.09.018.
    Full Text
  - Heist, Rebecca S., Xiaofei Wang, Lydia Hodgson, Gregory A. Otterson, Thomas E. Stinchcombe, Leena Gandhi, Miguel A. Villalona-Calero, et al. “CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 9, no. 2 (February 2014): 214–21. https://doi.org/10.1097/JTO.0000000000000071.
    Full Text
  - Berry, M. F., M. Worni, X. Wang, D. H. Harpole, T. A. D’Amico, and M. W. Onaitis. “Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival.” Annals of Thoracic Surgery 97, no. 1 (January 1, 2014): 230–35. https://doi.org/10.1016/j.athoracsur.2013.09.016.
    Full Text
  - Berry, Mark F., Mathias Worni, Xiaofei Wang, David H. Harpole, Thomas A. D’Amico, and Mark W. Onaitis. “Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival..” The Annals of Thoracic Surgery 97, no. 1 (January 2014): 230–35. https://doi.org/10.1016/j.athoracsur.2013.09.016.
    Full Text
  - Jiao, W., Y. Zhao, X. Wang, and J. Zhao. “Video-assisted thoracoscopic left upper lobe sleeve lobectomy combined with pulmonary arterioplasty via two-port approach.” Journal of Thoracic Disease 6, no. 12 (January 1, 2014): 1813–15. https://doi.org/10.3978/j.issn.2072-1439.2014.11.09.
    Full Text
  - Song, Z., Z. Zhang, B. Ge, X. Wang, and T. A. D’Amico. “Surgical techniques and results of the pulmonary artery reconstruction for patients with central non-small cell lung cancer.” Journal of Cardiothoracic Surgery 8, no. 1 (December 1, 2013). https://doi.org/10.1186/1749-8090-8-219.
    Full Text
  - Ma, Qianli, Deruo Liu, Yongqing Guo, Bin Shi, Zhiyi Song, Yan-chu Tian, Bingsheng Ge, Xiaofei Wang, and Thomas A. D. Amico. “SURGICAL TECHNIQUES AND RESULTS OF RECONSTRUCTION OF THE PULMONARY ARTERY FOR PATIENTS WITH CENTRAL NON-SMALL CELL LUNG CANCER.” Journal of Thoracic Oncology 8 (November 1, 2013): S217–S217.
    Link to Item
  - Pang, Herbert, Lydia Hodgson, Robert Kratzke, Jeffrey Crawford, Hedy Kindler, Everett Vokes, and Xiaofei Wang. “VALIDATION OF THE CALGB AND EORTC PROGNOSTIC MODELS FOR MESOTHELIOMA BASED ON MULTIPLE CALGB TRIALS (ALLIANCE).” Journal of Thoracic Oncology 8 (November 1, 2013): S934–35.
    Link to Item
  - Boylan, Alice M., Xiaofei F. Wang, Richard Ko, Patricia M. Watson, Lin Gu, David Harpole, Raphael Bueno, Rosemary Kelly, Leslie Kohman, and Robert Kratzke. “Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902..” The Journal of Thoracic and Cardiovascular Surgery 146, no. 1 (July 2013): 206–11. https://doi.org/10.1016/j.jtcvs.2012.08.059.
    Full Text
  - Jaklitsch, Michael T., Lin Gu, Todd Demmy, David H. Harpole, Thomas A. D’Amico, Robert J. McKenna, Mark J. Krasna, et al. “Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803..” The Journal of Thoracic and Cardiovascular Surgery 146, no. 1 (July 2013): 9–16. https://doi.org/10.1016/j.jtcvs.2012.12.069.
    Full Text
  - Boylan, A. M., X. F. Wang, R. Ko, P. M. Watson, L. Gu, D. Harpole, R. Bueno, R. Kelly, L. Kohman, and R. Kratzke. “Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: Results from Cancer and Leukemia Group B 159902.” Journal of Thoracic and Cardiovascular Surgery 146, no. 1 (2013): 206–11. https://doi.org/10.1016/j.jtcvs.2012.08.059.
    Full Text
  - Wang, Xiaofei, Junling Ma, and Stephen L. George. “ROC curve estimation under test-result-dependent sampling..” Biostatistics 14, no. 1 (January 2013): 160–72. https://doi.org/10.1093/biostatistics/kxs020.
    Full Text Link to Item
  - Demmy, Todd L., Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D’Amico, Susan Sutherland, Xiaofei Wang, et al. “Optimal management of malignant pleural effusions (results of CALGB 30102)..” Journal of the National Comprehensive Cancer Network : Jnccn 10, no. 8 (August 2012): 975–82. https://doi.org/10.6004/jnccn.2012.0102.
    Full Text
  - Chen, J., X. Wang, D. Yang, and B. Fan. “Nonparametric modeling auxiliary covariates in random coefficient models.” Communications in Statistics: Simulation and Computation 41, no. 8 (July 2, 2012): 1271–81. https://doi.org/10.1080/03610918.2011.594535.
    Full Text
  - Jänne, Pasi A., Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, et al. “Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial..” J Clin Oncol 30, no. 17 (June 10, 2012): 2063–69. https://doi.org/10.1200/JCO.2011.40.1315.
    Full Text Link to Item
  - Edelman, Martin J., Lydia Hodgson, Xiaofei Wang, Robert A. Kratzke, and Everett E. Vokes. “Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 16 (June 2012): 2019–20. https://doi.org/10.1200/JCO.2011.41.4581.
    Full Text
  - Jahan, Thierry, Lin Gu, Robert Kratzke, Arkadiusz Dudek, Gregory A. Otterson, Xiaofei Wang, Mark Green, Everett E. Vokes, and Hedy Lee Kindler. “Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)..” Lung Cancer (Amsterdam, Netherlands) 76, no. 3 (June 2012): 393–96. https://doi.org/10.1016/j.lungcan.2011.11.014.
    Full Text
  - Xue, D. Q., C. Qian, L. Yang, and X. F. Wang. “Risk factors for surgical site infections after breast surgery: a systematic review and meta-analysis..” European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 38, no. 5 (May 2012): 375–81. https://doi.org/10.1016/j.ejso.2012.02.179.
    Full Text
  - Edelman, Martin J., Lydia Hodgson, Paula Y. Rosenblatt, Robert H. Christenson, Everett E. Vokes, Xiaofei Wang, and Robert Kratzke. “CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 7, no. 4 (April 2012): 649–54. https://doi.org/10.1097/JTO.0b013e31824a8db0.
    Full Text
  - Schroen, Anneke T., Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Robert Gray, Jacqueline Benedetti, Xiaofei F. Wang, et al. “Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 18, no. 1 (January 2012): 256–62. https://doi.org/10.1158/1078-0432.CCR-11-1633.
    Full Text
  - Wang, Xiaofei, Junling Ma, Stephen George, and Haibo Zhou. “Estimation of AUC or Partial AUC under Test-Result-Dependent Sampling..” Statistics in Biopharmaceutical Research 4, no. 4 (January 2012): 313–23. https://doi.org/10.1080/19466315.2012.692514.
    Full Text
  - Kawaguchi, A., G. G. Koch, and X. Wang. “Stratified multivariate Mann-Whitney estimators for the comparison of two treatments with randomization based covariance adjustment.” Statistics in Biopharmaceutical Research 3, no. 2 (December 1, 2011): 217–31. https://doi.org/10.1198/sbr.2010.10007.
    Full Text
  - Salama, Joseph K., Thomas E. Stinchcombe, Lin Gu, Xiaofei Wang, Karen Morano, Jeffrey A. Bogart, Jeffrey C. Crawford, et al. “Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105..” Int J Radiat Oncol Biol Phys 81, no. 4 (November 15, 2011): e269–74. https://doi.org/10.1016/j.ijrobp.2011.01.056.
    Full Text Link to Item
  - Edelman, Martin J., Lydia Hodgson, Xiaofei Wang, Robert Christenson, Scott Jewell, Everett Vokes, and Robert Kratzke. “Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 6, no. 11 (November 2011): 1902–6. https://doi.org/10.1097/JTO.0b013e31822a7383.
    Full Text
  - Masters, Gregory A., Xiaofei Wang, Lydia Hodgson, Thomas Shea, Everett Vokes, and Mark Green. “A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531..” Lung Cancer (Amsterdam, Netherlands) 74, no. 2 (November 2011): 258–63. https://doi.org/10.1016/j.lungcan.2011.03.015.
    Full Text
  - Schroen, Anneke T., Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Daniel Sargent, Jacqueline K. Benedetti, Walter M. Cronin, et al. “Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials..” Clinical Trials (London, England) 8, no. 5 (October 2011): 591–600. https://doi.org/10.1177/1740774511419683.
    Full Text
  - Wu, Yougui, and Xiaofei Wang. “Optimal weight in estimating and comparing areas under the receiver operating characteristic curve using longitudinal data..” Biometrical Journal. Biometrische Zeitschrift 53, no. 5 (September 2011): 764–78. https://doi.org/10.1002/bimj.201100033.
    Full Text
  - Govindan, Ramaswamy, Jeffrey Bogart, Thomas Stinchcombe, Xiaofei Wang, Lydia Hodgson, Robert Kratzke, Jennifer Garst, Timothy Brotherton, and Everett E. Vokes. “Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 23 (August 2011): 3120–25. https://doi.org/10.1200/JCO.2010.33.4979.
    Full Text
  - Janne, Pasi A., Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Lin Gu, Marzia Capelletti, Martin J. Edelman, et al. “OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406..” Journal of Thoracic Oncology 6, no. 6 (June 1, 2011): S447–48.
    Link to Item
  - Dubey, Sarita, Pasi A. Jänne, Lee Krug, Herbert Pang, Xiaofei Wang, Robin Heinze, Colleen Watt, et al. “A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5, no. 10 (October 2010): 1655–61. https://doi.org/10.1097/JTO.0b013e3181ec18db.
    Full Text
  - Ready, Neal, Pasi A. Jänne, Jeffrey Bogart, Thomas Dipetrillo, Jennifer Garst, Stephen Graziano, Lin Gu, et al. “Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5, no. 9 (September 2010): 1382–90. https://doi.org/10.1097/jto.0b013e3181eba657.
    Full Text
  - Schroen, Anneke T., Gina R. Petroni, Hongkun Wang, Robert Gray, Xiaofei F. Wang, Walter Cronin, Daniel J. Sargent, et al. “Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials..” Clinical Trials (London, England) 7, no. 4 (August 2010): 312–21. https://doi.org/10.1177/1740774510374973.
    Full Text
  - Graziano, Stephen L., Lin Gu, Xiaofei Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert Kratzke, et al. “Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5, no. 6 (June 2010): 810–17. https://doi.org/10.1097/jto.0b013e3181d89f95.
    Full Text
  - Wang, Xiaofei, and Haibo Zhou. “Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling..” Biometrics 66, no. 2 (June 2010): 502–11. https://doi.org/10.1111/j.1541-0420.2009.01280.x.
    Full Text Link to Item
  - Aupérin, Anne, Cecile Le Péchoux, Estelle Rolland, Walter J. Curran, Kiyoyuki Furuse, Pierre Fournel, Jose Belderbos, et al. “Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 13 (May 2010): 2181–90. https://doi.org/10.1200/jco.2009.26.2543.
    Full Text
  - Partridge, Ann H., Laura Archer, Alice B. Kornblith, Julie Gralow, Debjani Grenier, Edith Perez, Antonio C. Wolff, et al. “Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 14 (May 2010): 2418–22. https://doi.org/10.1200/JCO.2009.26.4671.
    Full Text
  - Bogart, Jeffrey A., Lydia Hodgson, Stephen L. Seagren, A William Blackstock, Xiaofei Wang, Robert Lenox, Andrew T. Turrisi, et al. “Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 2 (January 2010): 202–6. https://doi.org/10.1200/JCO.2009.25.0753.
    Full Text
  - Wang, Xiaofei, Yougui Wu, and Haibo Zhou. “Outcome- and auxiliary-dependent subsampling and its statistical inference..” Journal of Biopharmaceutical Statistics 19, no. 6 (November 2009): 1132–50. https://doi.org/10.1080/10543400903243025.
    Full Text
  - D’Cunha, Jonathan, Xiaofei Wang, Shawn S. Groth, Robin T. Vollmer, Naif Z. Abraham, Debra L. Herzan, Lin Gu, et al. “The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: final analysis of CALGB 9761.” Journal of Thoracic Oncology 4, no. 9 (September 1, 2009): S576–S576.
    Link to Item
  - Govindan, Ramaswamy, Jeff Bogart, Xiaofei Wang, Lydia Hodgson, Robert A. Kratzke, and Everett E. Vokes. “A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.” Journal of Thoracic Oncology 4, no. 9 (September 1, 2009): S371–72.
    Link to Item
  - Lilenbaum, Rogerio, Xiaofei Wang, Lin Gu, Jeffrey Kirshner, Keith Lerro, and Everett Vokes. “Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 27 (September 2009): 4487–91. https://doi.org/10.1200/JCO.2009.22.7066.
    Full Text
  - Govindan, Ramaswamy, Xiaofei Wang, Maria Q. Baggstrom, Susan Burdette-Radoux, Lydia Hodgson, Everett E. Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 4, no. 2 (February 2009): 220–26. https://doi.org/10.1097/jto.0b013e3181951eb0.
    Full Text
  - Liptay, Michael J., Thomas A. D’amico, Chumy Nwogu, Todd L. Demmy, Xiaofei F. Wang, Lin Gu, Virginia R. Litle, Scott J. Swanson, Leslie J. Kohman, and Leslie J. Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B. “Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 4, no. 2 (February 2009): 198–202. https://doi.org/10.1097/jto.0b013e318194a2c3.
    Full Text
  - Miller, Antonius A., Xiaofei F. Wang, Lin Gu, Philip Hoffman, Jamil Khatri, Frank Dunphy, Martin J. Edelman, et al. “Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 3, no. 10 (October 2008): 1159–65. https://doi.org/10.1097/jto.0b013e318186fb0d.
    Full Text
  - Socinski, Mark A., A William Blackstock, Jeffrey A. Bogart, Xiaofei Wang, Michael Munley, Julian Rosenman, Lin Gu, et al. “Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 15 (May 2008): 2457–63. https://doi.org/10.1200/jco.2007.14.7371.
    Full Text
  - Kratzke, Robert A., Xiaofei Wang, Long Wong, Marian G. Kratzke, Mark R. Green, Everett E. Vokes, Nicholas J. Vogelzang, Hedy L. Kindler, Jeffrey A. Kern, and Jeffrey A. Cancer and Leukemia Group B. “Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 3, no. 4 (April 2008): 417–21. https://doi.org/10.1097/jto.0b013e318168da0a.
    Full Text
  - Edelman, Martin J., Dee Watson, Xiaofei Wang, Carl Morrison, Robert A. Kratzke, Scott Jewell, Lydia Hodgson, et al. “Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 6 (February 2008): 848–55. https://doi.org/10.1200/jco.2007.13.8081.
    Full Text
  - Graziano, Stephen L., James E. Herndon, Mark A. Socinski, Xiaofei Wang, Dorothy Watson, Everett Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 3, no. 2 (February 2008): 158–62. https://doi.org/10.1097/jto.0b013e318161225e.
    Full Text
  - Rudin, Charles M., Ravi Salgia, Xiaofei Wang, Lydia D. Hodgson, Gregory A. Masters, Mark Green, and Everett E. Vokes. “Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 6 (February 2008): 870–76. https://doi.org/10.1200/JCO.2007.14.3461.
    Full Text
  - Graziano, Stephen L., Lin Gu, Xiaofei F. Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert A. Kratzke, Mark R. Green, and Everett E. Vokes. “D5-01: Prognostic significance of molecular markers and clinical factors in stage ib non-small cell lung cancer (NSCLC): a laboratory companion study to CALGB 9633.” Journal of Thoracic Oncology 2, no. 8 (August 2007): S403–S403. https://doi.org/10.1097/01.jto.0000283278.97704.03.
    Full Text
  - Miller, Antonius A., Xiaofei F. Wang, Jeffrey A. Bogart, Lydia D. Hodgson, Caio M. S. Rocha Lima, James E. Radford, Everett E. Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B (CALGB). “Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 2, no. 7 (July 2007): 645–51. https://doi.org/10.1097/jto.0b013e318074bbf5.
    Full Text
  - Perry, Michael C., Leslie J. Kohman, James A. Bonner, Lin Gu, Xiaofei Wang, Everett E. Vokes, and Mark R. Green. “A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734..” Clinical Lung Cancer 8, no. 4 (January 2007): 268–72. https://doi.org/10.3816/clc.2007.n.005.
    Full Text
  - Wang, Xiaofei, and Haibo Zhou. “A semiparametric empirical likelihood method for biased sampling schemes with auxiliary covariates..” Biometrics 62, no. 4 (December 2006): 1149–60. https://doi.org/10.1111/j.1541-0420.2006.00612.x.
    Full Text
  - Riedel, Richard F., Xiaofei Wang, Meg McCormack, Eric Toloza, Gustavo S. Montana, Gilbert Schreiber, and Michael J. Kelley. “Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 1, no. 7 (September 2006): 692–96. https://doi.org/10.1016/s1556-0864(15)30383-x.
    Full Text
  - Pincus, T., X. Wang, C. Chung, T. Sokka, and G. G. Koch. “Erratum: Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings (Journal of Rheumatology (2005) 32 (533-539)).” Journal of Rheumatology 32, no. 5 (May 1, 2005).
  - Pincus, Theodore, Xiaofei Wang, Cecilia Chung, Tuulikki Sokka, and Gary G. Koch. “Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of self-report questionnaire ratings..” The Journal of Rheumatology 32, no. 3 (March 2005): 533–39.
  - Wang, Youfa, and Xiaofei Wang. “How do statistical properties influence findings of tracking (maintenance) in epidemiologic studies? An example of research in tracking of obesity..” European Journal of Epidemiology 18, no. 11 (January 2003): 1037–45. https://doi.org/10.1023/a:1026196310041.
    Full Text
  - Wang, Youfa, and Xiaofei Wang. “Re: "Tracking of cardiovascular risk factors: the Tromsø Study, 1979, 1995"..” American Journal of Epidemiology 155, no. 12 (June 2002): 1144–45. https://doi.org/10.1093/aje/155.12.1144.
    Full Text
  - Pincus, T., G. G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J. M. Jordan, G. Luta, et al. “A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee..” Arthritis and Rheumatism 44, no. 7 (July 2001): 1587–98. https://doi.org/10.1002/1529-0131(200107)44:7<1587::aid-art282>3.0.co;2-x.
    Full Text
  - Pincus, T., G. G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J. M. Jordan, G. Luta, et al. “A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.” Arthritis and Rheumatism 44, no. 7 (2001): 1587–98. https://doi.org/10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X.
    Full Text
  - Wang, X., and C. A. Burbeck. “Scaled medial axis representation: evidence from position discrimination task..” Vision Research 38, no. 13 (June 1998): 1947–59. https://doi.org/10.1016/s0042-6989(97)00299-x.
    Full Text
  - Wang, X. F., and C. A. Burbeck. “Enhanced position sensitivity at scaled medial loci.” Investigative Ophthalmology and Visual Science 37, no. 3 (February 15, 1996).
- Book Sections
  - George, S. L., X. Wang, and H. Pang. “Preface,” 2016. https://doi.org/10.1201/9781315371566.
    Full Text
  - George, S. L., X. Wang, and H. Pang. “Preface,” 2016. https://doi.org/10.1201/9781315371566.
    Full Text
  - George, S. L., X. Wang, and H. Pang. “Preface,” 2016. https://doi.org/10.1201/9781315371566.
    Full Text
  - George, S. L., and X. Wang. “Targeted clinical trials.” In Designs for Clinical Trials: Perspectives on Current Issues, 157–77, 2012. https://doi.org/10.1007/978-1-4614-0140-7_7.
    Full Text
  - George, S. L., and X. Wang. “Targeted clinical trials.” In Designs for Clinical Trials: Perspectives on Current Issues, 157–77, 2012. https://doi.org/10.1007/978-1-4614-0140-7_7.
    Full Text
- Conference Papers
  - Wang, Ting, Xiaofei Wang, Haibo Zhou, Jianwen Cai, and Stephen L. George. “Biomarker stratified design enriched by auxiliary variables.” In Trials, Vol. 18. BIOMED CENTRAL LTD, 2017.
    Link to Item
  - Yi, John, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, and Mark W. Onaitis. “Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC)..” In Journal of Clinical Oncology, Vol. 35. AMER SOC CLINICAL ONCOLOGY, 2017.
    Link to Item
  - Pang, Herbert, Kang Yan, Robert Kratzke, Thomas Stinchcombe, Jeffrey Crawford, Hedy Kindler, Everett Vokes, and Xiaofei Wang. “Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance).” In Journal of Thoracic Oncology, 12:S1367–S1367. ELSEVIER SCIENCE INC, 2017.
    Link to Item
  - Stinchcombe, Thomas, Ying Zhang, Everett Vokes, Joan Schiller, Jeffrey Bradley, Karen Kelly, Walter Curran, et al. “A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC.” In Journal of Thoracic Oncology, 12:S374–75. ELSEVIER SCIENCE INC, 2017.
    Link to Item
  - Wang, Xiaofei, Xiaowen Cao, Thomas Stinchcombe, Jeffrey Bradley, Alex Adjei, David R. Gandara, Suresh Ramalingam, Herbert Pang, Everett Vokes, and Jeffrey Crawford. “Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials.” In Journal of Thoracic Oncology, 12:S922–23. ELSEVIER SCIENCE INC, 2017.
    Link to Item
  - Stinchcombe, Tom, Ying J. Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Walter John Curran, Benjamin Movsas, et al. “A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts)..” In Journal of Clinical Oncology, 34:8508–8508. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.8508.
    Full Text
  - Yang, Chi-Fu Jeffrey, Derek Y. Chan, Babatunde Yerokun, Xiaofei F. Wang, Betty Caroline Tong, Thomas A. D’Amico, Mark W. Onaitis, Matthew G. Hartwig, Mark F. Berry, and David Harpole. “Surgery versus optimal medical management of early-stage small cell lung cancer..” In Journal of Clinical Oncology, 34:8511–8511. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.8511.
    Full Text
  - Edelman, Martin J., Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Baggstrom, Thomas Sachdev, Ajeet Gajra, et al. “Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance).” In Cancer Research, 74:CT238–CT238. American Association for Cancer Research (AACR), 2014. https://doi.org/10.1158/1538-7445.am2014-ct238.
    Full Text
  - Socinski, Mark A., Xiaofei F. Wang, Maria Quintos Baggstrom, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker JR, Heather Dorothy Mannuel, Jeffrey Crawford, and Everett E. Vokes. “Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial..” In Journal of Clinical Oncology, 32:8040–8040. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.8040.
    Full Text
  - Stinchcombe, Tom, Lynette M. Sholl, Xiaofei F. Wang, Lin Gu, Mark A. Socinski, Scott J. Rodig, Marzia Capelletti, et al. “An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC)..” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Pang, Herbert, Lin Gu, William Richards, Jeffery Crawford, Mark Green, Everett Vokes, and Xiaofei Wang. “Abstract 4707: Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups..” In Cancer Research, 73:4707–4707. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-4707.
    Full Text
  - Heist, Rebecca Suk, Xiaofei F. Wang, Lydia Hodgson, Gregory Alan Otterson, Tom Stinchcombe, Everett E. Vokes, and Mark A. Socinski. “CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Janne, Pasi A., Xiaofei F. Wang, Lee M. Krug, Lydia Hodgson, Everett E. Vokes, and Hedy L. Kindler. “Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307.” In Annals of Oncology, 17:216–17. OXFORD UNIV PRESS, 2006.
    Link to Item
Teaching & Mentoring
Recent Courses
- BIOSTAT 708: Clinical Trial Design and Analysis 2018
Scholarly, Clinical, & Service Activities
Service to the Profession

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Global Scholarship

Expertise

Selected Grants

Selected Publications

Books

Academic Articles

Book Sections

Conference Papers

Recent Courses

Service to the Profession